Boehringer Ingelheim Pharma GmbH & Co. KG (manufacturing, primary and secondary packaging, labeling, quality control, including stability studies and batch release)
UkraineAll drugs from this manufacturer
-
The drug is intended for adults for the treatment of signs and symptoms of idiopathic Parkinson's disease. It can be used either as monotherapy or in combination with levodopa.
Dosage form: tablets, extended-release
Active substance Dosage pramipexole 0.26 mg ATC: N04BC05
-
The drug is intended for adults for the treatment of signs and symptoms of idiopathic Parkinson's disease. It can be used either as monotherapy or in combination with levodopa.
Dosage form: tablets, extended-release
Active substance Dosage pramipexole 0.52 mg ATC: N04BC05
-
The drug is indicated for adults for the treatment of signs and symptoms of idiopathic Parkinson's disease. It can be used as monotherapy or in combination with levodopa.
Dosage form: tablets, extended-release
Active substance Dosage pramipexole 1.05 mg ATC: N04BC05